Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Tetra Bio-Pharma Inc. (C:TBP)

Business Focus: Alternative Medicine

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for TBP within the last 6 months
See all filings within the past 6 months

Company News

Aug 01, 2023 07:30 ET
Tetra Bio-Pharma Voluntary Bankruptcy
Montreal – TheNewswire - August 1, 2023 – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTC:TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced that it has made a voluntary assignment into bankruptcy under the Bankruptcy and Insolvency Act (Canada). HOULE ROY S.A. (the “Trustee”) has been appointed as Tetra’s trustee in bankruptcy.
Read full article
May 11, 2023 10:45 ET
Tetra Bio-Pharma Cancels New Drug Submission to Health Canada
MONTREAL, QUEBEC – TheNewswire – May 11, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, today announced it has cancelled its New Drug Submission (NDS) to Health Canada, without prejudice to a refiling once it has completed a new clinical trial that addresses deficiencies raised by the regulator.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 196900
Dec 31, 196900
Dec 31, 196900
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

See business summary



Search (past week) for $TBP.CA

  • No tweets found